Initial COVID-19 Vaccination is Highly Immunogenic and Safe: A Stop the Spread Ottawa Cohort Analysis

Alexa Keeshan1, Yannick Galipeau2, Aliisa Heiskanen1, Erin Collins1, Corey Arnold3, Raphael Saginur2, Ronald Booth2, Julian Little2, Michaeline Mcguinty2, Arianne Buchan2, Angela Crawley3, Marc-André Langlois2, and Curtis Cooper4

1University of Ottawa School of Epidemiology and Public Health
2University of Ottawa
3University of Ottawa Department of Biochemistry Microbiology and Immunology
4Ottawa Hospital Research Institute

May 5, 2023

Abstract

INTRODUCTION: Predictors of COVID-19 vaccine immunogenicity and the influence of prior SARS-CoV-2 infection require elucidation. METHODS: Stop the Spread Ottawa is a prospective cohort of individuals at-risk for or who have been infected with SARS-CoV-2, initially enrolled for 10 months beginning October 2020. This analysis focuses on safety and immunogenicity of the initial two doses of COVID-19 vaccine. RESULTS: Post-vaccination data with blood specimens were available for 930 participants. 22.8% were SARS-CoV2 infected prior to first vaccine dose. Cohort characteristics include: median age 44 (22, 56), 66.6% female, 89.0% white, 83.2% employed. 38.1% reported two or more comorbidities and 30.8% reported immune compromising condition(s). Over 95% possessed IgG spike and RBD titres 3 months post second vaccine dose. By multivariable analysis, increasing age and high-level immune compromise predicted diminishing IgG spike and RBD titres at month 3 post second dose. IgG spike and RBD titres were higher immediately post vaccination in those with SARS-CoV-2 infection prior to first vaccination and spike titres were higher at 6 months in those with wider time intervals between dose 1 and 2. IgG spike and RBD titres and neutralization were generally similar by sex, weight and whether receiving homogeneous or heterogeneous combinations of vaccines. Common post dose 1 vaccine symptoms included fatigue (64.7%), injection site pain (47.5%), headache (27.2%), fever/chills (26.2%), body aches (25.3%). These symptoms are similar with subsequent doses. CONCLUSION: The initial two COVID-19 vaccine doses are safe, well-tolerated and highly immunogenic across a broad spectrum of vaccine recipients.

Hosted file
